Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE

Kimyli Recca; Aeman Muneeb; Christopher Helstern; Bryan Lemieux; Satya Das; Aaron Jessop

doi:10.1097/HP.0000000000001611

Evaluation of Patient Transmission Factor Following the Administration of ¹⁷⁷Lu-DOTATATE

Kimyli Recca, Aeman Muneeb, Christopher Helstern, Bryan Lemieux, Satya Das, Aaron Jessop

Research output: Contribution to journal › Article › peer-review

Abstract

177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public, ensuring that the total effective dose equivalent (TEDE) does not exceed regulatory limits. If the calculated TEDE meets the regulatory limits, the patient is eligible for release and provided instructions with radiation precautions. This study aims to determine a mean transmission factor to the patient to improve accuracy and individualize the estimation of the TEDE.

Original language	English (US)
Pages (from-to)	457-463
Number of pages	7
Journal	Health physics
Volume	123
Issue number	6
DOIs	https://doi.org/10.1097/HP.0000000000001611
State	Published - Dec 1 2022
Externally published	Yes

Keywords

attenuation
nuclear medicine
radiopharmaceuticals
tumors

ASJC Scopus subject areas

General Medicine

Access to Document

10.1097/HP.0000000000001611

Cite this

@article{4be2eb329ce44135904a665440250491,

title = "Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE",

abstract = "177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public, ensuring that the total effective dose equivalent (TEDE) does not exceed regulatory limits. If the calculated TEDE meets the regulatory limits, the patient is eligible for release and provided instructions with radiation precautions. This study aims to determine a mean transmission factor to the patient to improve accuracy and individualize the estimation of the TEDE.",

keywords = "attenuation, nuclear medicine, radiopharmaceuticals, tumors",

author = "Kimyli Recca and Aeman Muneeb and Christopher Helstern and Bryan Lemieux and Satya Das and Aaron Jessop",

note = "Publisher Copyright: {\textcopyright} Lippincott Williams & Wilkins.",

year = "2022",

month = dec,

day = "1",

doi = "10.1097/HP.0000000000001611",

language = "English (US)",

volume = "123",

pages = "457--463",

journal = "Health physics",

issn = "0017-9078",

publisher = "Lippincott Williams and Wilkins",

number = "6",

}

TY - JOUR

T1 - Evaluation of Patient Transmission Factor Following the Administration of 177Lu-DOTATATE

AU - Recca, Kimyli

AU - Muneeb, Aeman

AU - Helstern, Christopher

AU - Lemieux, Bryan

AU - Das, Satya

AU - Jessop, Aaron

N1 - Publisher Copyright: © Lippincott Williams & Wilkins.

PY - 2022/12/1

Y1 - 2022/12/1

N2 - 177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public, ensuring that the total effective dose equivalent (TEDE) does not exceed regulatory limits. If the calculated TEDE meets the regulatory limits, the patient is eligible for release and provided instructions with radiation precautions. This study aims to determine a mean transmission factor to the patient to improve accuracy and individualize the estimation of the TEDE.

AB - 177Lu-DOTATATE is a radionuclide therapy that is FDA approved for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Treatment facilities are required to determine the maximum radiation dose from such subjects to the maximally exposed member of the public, ensuring that the total effective dose equivalent (TEDE) does not exceed regulatory limits. If the calculated TEDE meets the regulatory limits, the patient is eligible for release and provided instructions with radiation precautions. This study aims to determine a mean transmission factor to the patient to improve accuracy and individualize the estimation of the TEDE.

KW - attenuation

KW - nuclear medicine

KW - radiopharmaceuticals

KW - tumors

UR - http://www.scopus.com/inward/record.url?scp=85141481027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141481027&partnerID=8YFLogxK

U2 - 10.1097/HP.0000000000001611

DO - 10.1097/HP.0000000000001611

M3 - Article

C2 - 36099424

AN - SCOPUS:85141481027

SN - 0017-9078

VL - 123

SP - 457

EP - 463

JO - Health physics

JF - Health physics

IS - 6

ER -